How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,545 results for

Diarrhea in Cancer

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D)

of at least 4 weeks duration. This would exclude those patients with bloody diarrhea; diarrhea with signs of fat malabsorption; presentations with alarm features, such as weight loss, anemia, and hypoalbuminemia; those patients with a family history of inflammatory bowel disease (IBD), colon cancer, or celiac disease; and those with a travel history to regions with recognized specific diarrhea-related pathogens. This guideline was developed using a process outlined elsewhere. x 1 American (...) AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) - Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search Access provided by Volume 157, Issue 3, Pages 851–854 AGA Clinical Practice

2019 American Gastroenterological Association Institute

2. Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials. (PubMed)

Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials. We performed an meta-analysis to fully investigate the diarrhea of EGFR-TKIs in cancer patients. The relevant studies of the randomized controlled trials (RCTs) in cancer patients treated with EGFR-TKIs were retrieved and the systematic evaluation was conducted. EMBASE, MEDLINE, and PubMed were searched for articles published till August 2017 (...) . The relevant RCTs in cancer patients treated with EGFR-TKIs were retrieved and the systematic evaluation was conducted. Twenty-four RCTs and 13,748 patients were included. The current analysis suggested that the use of EGFR-TKIs increased the risk of all-grade diarrhea (RR 3.45; 95%CI, 2.94-4.06; p<0.00001) and high-grade (≥grade 3) diarrhea (RR 8.22;95%CI, 6.02-11.23; p<0.00001). On subgroup analysis, the risk of all-grade and high-grade diarrhea varied significantly within drug type. The risk of all

2019 Critical reviews in oncology/hematology

3. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial. (PubMed)

Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial. We characterized patterns of occurrence and the impact of neratinib-associated diarrhea in the absence of protocol-directed antidiarrheal prophylaxis or a formal diarrhea management plan using data from Extended Adjuvant Treatment of Breast Cancer with Neratinib (ExteNET).ExteNET is a multicenter, double-blind, placebo (...) -controlled, randomized phase III trial involving community-based and academic institutions in 40 countries. Women with HER2-positive early-stage breast cancer with prior standard primary therapy and trastuzumab-based (neo)adjuvant therapy were randomized to neratinib 240 mg/day or placebo for 12 months. Safety, a secondary outcome, was assessed using the National Cancer Institute Common Terminology Criteria version 3.0. Health-related quality of life by diarrhea grade was assessed using Functional

Full Text available with Trip Pro

2019 Breast cancer research : BCR

4. Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer. (PubMed)

Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer. Angiogenesis is a proven clinical target for the treatment of advanced epithelial ovarian cancer. Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) offer patients potential new treatment regimens as they can be given as monotherapy, in combination with poly(ADP-ribose) polymerase (PARP) inhibitors, or with and following cytotoxic chemotherapy. If VEGFR (...) -TKIs are licensed for use in ovarian cancer, patients will require prompt and effective management of adverse events, including diarrhea, to optimize compliance and benefit. As diarrhea is one of the most prevalent toxicities of this class of drug, it is important to consider the potential causes, be they disease related (bowel obstruction), treatment related (VEGFR-TKI-related or infective/neutropenic septic diarrhea when patients are receiving cytotoxic chemotherapy combined with VEGFR inhibitor

2018 Gynecologic Oncology

5. Diarrhea and flatulence are major bowel disorders after radical cystectomy: Results from a cross-sectional study in bladder cancer patients. (PubMed)

Diarrhea and flatulence are major bowel disorders after radical cystectomy: Results from a cross-sectional study in bladder cancer patients. We had previously demonstrated changes in defecation after radical cystectomy (RC). Reports addressing long-term bowel disorders following RC are rare. This cross-sectional study evaluates long-term bowel issues in a large cohort.A questionnaire assessing changes in bowel function (diarrhea, constipation, urge to defecate, sensation of incomplete (...) defecation, and flatulence) and its effect on quality of life was developed based on the gastrointestinal quality of life index and distributed in collaboration with the German bladder cancer support group. There were 431 evaluable questionnaires. For the analyses, we focused on patients that had the RC>1 year ago (n = 324).Current bowel problems were reported by 42.6% of patients. The most frequent bowel problems were flatulence (48.8%), diarrhea (29.6%), and sensation of incomplete defecation (22.5

2018 Urologic oncology

6. Treatment of Enteropathogenic Escherichia coli Diarrhea in Cancer Patients: A Series of Three Cases (PubMed)

Treatment of Enteropathogenic Escherichia coli Diarrhea in Cancer Patients: A Series of Three Cases Enteropathogenic Escherichia coli (EPEC) is a common cause of watery diarrhea in children in the developing world and an infrequent cause of significant diarrhea in adult patients. EPEC diarrhea, while not commonly seen in cancer patients, can cause significant distress to patients, and antimicrobial choice for this condition in this patient population is not clearly delineated in the literature (...) . We report 3 cases of EPEC diarrhea in cancer patients and discuss the use of azithromycin for successful treatment of these patients. Positive outcomes were seen while using azithromycin in our first two patients and ciprofloxacin in our third patient.

Full Text available with Trip Pro

2018 Case reports in infectious diseases

7. Fructus mume Extracts Alleviate Diarrhea in Breast Cancer Patients Receiving the Combination Therapy of Lapatinib and Capecitabine (PubMed)

Fructus mume Extracts Alleviate Diarrhea in Breast Cancer Patients Receiving the Combination Therapy of Lapatinib and Capecitabine Lapatinib and capecitabine have been widely used in the therapy of breast cancer. However, long-term use of lapatinib and capecitabine often causes the most common side effect diarrhea, which limit the medicine use. Fructus mume (F. mume) has been proved to be effective to treat chronic diarrhea with few side effects. The compounds from F. mume were extracted (...) by using an ethanol method. Extracts of F. mume (EFM) were analyzed by HPLC. We investigated the protective effects of EFM on the diarrhea caused by lapatinib and capecitabine. From March 1st, 2016 to June 1st, 2017, 208 breast cancer patients with diarrhea caused by lapatinib and capecitabine were recruited. The patients were evenly assigned into two groups: EG group (the patients took 100 mg EFM daily) and CG group (the patients took placebo daily). The effects of EFM on diarrhea and gastrointestinal

Full Text available with Trip Pro

2018 Frontiers in pharmacology

8. Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer (PubMed)

Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer Irinotecan (CPT-11) can be used as a first-line therapeutic drug against extensive-stage small cell lung cancer (SCLC); it can also be used in second-line treatment for SCLC. CPT-11-induced delayed diarrhea restricts its clinical application. This study aimed to confirm whether Banxia Xiexin decoction was effective in preventing and controlling CPT-11-induced (...) delayed diarrhea.A total of 27 patients with recurrent SCLC undergoing chemotherapy regimens including CPT-11 were enrolled for the study. UGT1A1*28, UGTlAl*6, ABCB1*2, and SLCO1B1*15 gene polymorphisms were detected. If delayed diarrhea occurred in the first cycle of chemotherapy, Banxia Xiexin decoction was orally administered for 5 consecutive days starting 1 day before the second cycle of chemotherapy to prevent and control the delayed diarrhea. The objective response, overall survival

Full Text available with Trip Pro

2018 Integrative cancer therapies

9. Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials (PubMed)

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials Afatinib is an effective therapy for metastatic non-small cell lung cancer (NSCLC) but it is associated with a relatively high incidence of severe diarrhea. The association between pre-treatment candidate predictors (age, sex, race, performance status, renal function, hemoglobin, and measures of body mass) and severe (grade ≥ 3) diarrhea was evaluated using logistic (...) regression with pooled individual participant data from seven clinical studies. A risk score was developed based on the count of major risk factors. Overall, 184 of 1151 participants (16%) experienced severe diarrhea with use of afatinib. Body weight, body mass index, and body surface area all exhibited a prominent non-linear association where risk increased markedly at the lower range (p < 0.005). Low weight (<45 kg), female sex, and older age (≥60 years) were identified as major independent risk

Full Text available with Trip Pro

2018 Cancers

10. Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea

Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea | Clinical Infectious Diseases | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite (...) Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation 15 December 2017 Article Contents Article Navigation 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea Andi L Shane, MD Division of Infectious Diseases, Department of Pediatrics, Emory University and Children’s Healthcare of Atlanta, Atlanta, Georgia Correspondence: A. L. Shane, MD, MPH, MSc, Associate

Full Text available with Trip Pro

2017 Infectious Diseases Society of America

11. Radiation-Induced Diarrhea

Radiation-Induced Diarrhea Radiation-Induced Diarrhea | ONS Hello [ Name ] ! Renew Membership: Hello [ Name ] ! Renew Membership: Menu Search Radiation-Induced Diarrhea Diarrhea is an abnormal increase in stool liquidity and frequency that may be accompanied by abdominal cramping. Cancer-related diarrhea can be seen in patients with carcinoid tumors, carcinoid syndrome, gastrointestinal tumors, and hormone-producing tumors. Patients undergoing high-dose chemotherapy and patients receiving (...) radiation therapy to abdominal and pelvic areas are more susceptible to diarrhea. Certain chemotherapy, biotherapy, and targeted therapies and regimens are associated with greater risk of diarrhea. In patients receiving chemotherapy, the incidence of diarrhea can range from 50%–90%. Radiation-induced diarrhea is seen most often with radiation to abdominal and pelvic fields. Acute radiation enteritis can be seen in up to 70% of patients, depending on treatment and patient predisposing factors. Late-onset

2017 Oncology Nursing Society Putting Evidence into Practice (PEP)

12. Chemotherapy-Induced Diarrhea

Chemotherapy-Induced Diarrhea Chemotherapy-Induced Diarrhea | ONS Hello [ Name ] ! Renew Membership: Hello [ Name ] ! Renew Membership: Menu Search Chemotherapy-Induced Diarrhea Diarrhea is an abnormal increase in stool liquidity and frequency that may be accompanied by abdominal cramping. Cancer-related diarrhea can be seen in patients with carcinoid tumors, carcinoid syndrome, gastrointestinal tumors, and hormone-producing tumors. Patients undergoing high-dose chemotherapy and patients (...) receiving radiation therapy to abdominal and pelvic areas are more susceptible to diarrhea. Certain chemotherapy, biotherapy, and targeted therapies and regimens are associated with greater risk of diarrhea. In patients receiving chemotherapy, the incidence of diarrhea can range from 50%–90%. Diarrhea can be a dose-limiting toxicity for certain chemotherapeutic agents. This topic was updated on February 27, 2017. . Likely to Be Effective Benefits Balanced with Harm Effectiveness Not Established Expert

2017 Oncology Nursing Society Putting Evidence into Practice (PEP)

13. Immunotherapy-Induced Diarrhea

Immunotherapy-Induced Diarrhea Immunotherapy-Induced Diarrhea | ONS Hello [ Name ] ! Renew Membership: Hello [ Name ] ! Renew Membership: Menu Search Immunotherapy-Induced Diarrhea Diarrhea is an abnormal increase in stool liquidity and frequency that may be accompanied by abdominal cramping. Cancer-related diarrhea can be seen in patients with carcinoid tumors, carcinoid syndrome, gastrointestinal tumors, and hormone-producing tumors. Patients undergoing high-dose chemotherapy and patients (...) receiving radiation therapy to abdominal and pelvic areas are more susceptible to diarrhea. Certain chemotherapy, biotherapy, and targeted therapies and regimens are associated with greater risk of diarrhea. In patients receiving chemotherapy, the incidence of diarrhea can range from 50%–90%. Gastrointestinal side effects with immunotherapy can manifest as diarrhea, abdominal pain, or melena. The mechanism for development of diarrhea with immunotherapy is different from that with chemotherapy

2017 Oncology Nursing Society Putting Evidence into Practice (PEP)

14. Effects of fiber and probiotics on diarrhea associated with enteral nutrition in gastric cancer patients: A prospective randomized and controlled trial. (PubMed)

Effects of fiber and probiotics on diarrhea associated with enteral nutrition in gastric cancer patients: A prospective randomized and controlled trial. Diarrhea is a common complication of enteral nutrition (EN), which affects recovery and prolongs the length of hospital stay (LOHS). To investigate the effect of fiber and probiotics in reducing diarrhea associated with EN in postoperative patients with gastric cancer (GC), the authors designed this prospective randomized-controlled trial.This (...) study included 120 patients with GC, and the patients were classified into 3 groups via random picking of envelopes: fiber-free nutrition formula (FF group, n = 40), fiber-enriched nutrition formula (FE group, n = 40), and fiber- and probiotic-enriched nutrition formula (FEP group, n = 40). All patients were given EN formulas for 7 consecutive days after surgery.The number of diarrhea cases was higher in the FF group than in the FE group (P = .007). The FEP group had a lower number of diarrhea cases

Full Text available with Trip Pro

2017 Medicine

15. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. (PubMed)

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the incidence and severity of diarrhea observed with pertuzumab in the CLEOPATRA, NeoSphere, and TRYPHAENA (...) studies.Patients (n = 1443) had metastatic [CLEOPATRA (n = 804)] or early-stage breast cancer [NeoSphere (n = 416) and TRYPHAENA (n = 223)]. The incidence and severity of diarrhea were analyzed by treatment received. The incidence of febrile neutropenia concurrent with diarrhea and the effect of pre-existing gastrointestinal comorbidities were also evaluated. Subgroup analyses were carried out using CLEOPATRA data.The incidence of all-grade diarrhea across studies was generally greater for pertuzumab-based

Full Text available with Trip Pro

2017 Annals of Oncology

16. The Capsule Endoscopy Findings in S-1-induced Enteritis with Severe Diarrhea during Adjuvant Chemotherapy for Gastric Cancer (with Video) (PubMed)

The Capsule Endoscopy Findings in S-1-induced Enteritis with Severe Diarrhea during Adjuvant Chemotherapy for Gastric Cancer (with Video) Although S-1 chemotherapy is used widely as postoperative adjuvant chemotherapy for gastric cancer, some patients experience diarrhea during treatment. The patient was a 39-year-old woman who underwent distal gastrectomy for gastric cancer and who had started S-1 chemotherapy as postoperative adjuvant chemotherapy 1 week before her presentation. She (...) experienced severe diarrhea immediately after starting the course of S-1 tablets. Capsule endoscopy revealed severe S-1-induced enteritis with extensive mucosal injury in the ileum and red intestinal fluid due to the oozing of blood in the ileum. After reducing the dosage of S-1, her diarrhea became milder, and she was able to continue S-1 chemotherapy.

Full Text available with Trip Pro

2017 Internal Medicine

17. Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy

Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2017 Clinical Trials

18. Reduction in social activities mediates the relationship between diarrhea and distress in rectal/anal cancer survivors (PubMed)

Reduction in social activities mediates the relationship between diarrhea and distress in rectal/anal cancer survivors 28665010 2019 01 24 1099-1611 27 2 2018 02 Psycho-oncology Psychooncology Reduction in social activities mediates the relationship between diarrhea and distress in rectal/anal cancer survivors. 691-694 10.1002/pon.4486 Benedict Catherine C 0000-0001-9622-249X Hofstra Northwell School of Medicine, Manhasset, NY, USA. DuHamel Katherine K 0000-0002-4519-6057 Memorial Sloan (...) Kettering Cancer Center, New York, NY, USA. Nelson Christian J CJ Memorial Sloan Kettering Cancer Center, New York, NY, USA. eng P30 CA008748 CA NCI NIH HHS United States R21 CA129195 CA NCI NIH HHS United States R21 CA137434 CA NCI NIH HHS United States T32 CA009461 CA NCI NIH HHS United States Journal Article Research Support, N.I.H., Extramural 2017 08 02 England Psychooncology 9214524 1057-9249 2016 12 06 2017 05 09 2017 06 19 2017 7 1 6 0 2017 7 1 6 1 2017 7 1 6 0 ppublish 28665010 10.1002/pon.4486

Full Text available with Trip Pro

2017 Psycho-oncology

19. Genotyping of Enterocytozoon bieneusi and Subtyping of Blastocystis in Cancer Patients: Relationship to Diarrhea and Assessment of Zoonotic Transmission (PubMed)

Genotyping of Enterocytozoon bieneusi and Subtyping of Blastocystis in Cancer Patients: Relationship to Diarrhea and Assessment of Zoonotic Transmission Enterocytozoon bieneusi (E. bieneusi) and Blastocystis are common pathogens responsible for diarrhea in humans, especially in immunocompromised individuals. The number of cancer patients has been increasing and diarrhea is a common clinical symptom in the treatment of cancers. To understand the prevalences and genotypes/subtypes of E. bieneusi (...) and Blastocystis in cancer patients in China, to track the infection sources, and to explore the relationships between E. bieneusi and Blastocystis infections and diarrhea, 381 fecal specimens were collected from cancer patients. Each of them was analyzed for the presence of E. bieneusi and Blastocystis by PCR amplifying and sequencing the ITS region of the rRNA gene and the barcode region of the SSU rRNA gene, respectively. 1.3 and 7.1% of cancer patients were positive for E. bieneusi and Blastocystis

Full Text available with Trip Pro

2017 Frontiers in microbiology

20. Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer (PubMed)

Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer Diarrhea and oral mucositis induced by afatinib can cause devastating quality of life issues for patients undergoing afatinib treatment. Several studies have shown that hangeshashin-to (TJ-14) might be useful for chemotherapy-induced diarrhea and oral mucositis. In this study, we investigated the prophylactic effects of TJ-14 (...) for afatinib-induced diarrhea and oral mucositis and minocycline for afatinib-induced skin rash.First- and second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have become the standard first-line treatment in patients with EGFR-mutated non-small cell lung cancer. The incidence of diarrhea was higher with afatinib than with gefitinib, and we conducted a single-arm Phase II study with afatinib. Patients who had previously undergone treatment with afatinib were ineligible. Both

Full Text available with Trip Pro

2017 OncoTargets and therapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>